Home › MDWD
Biotechnology
MDWD
1.38
  Price2.82%   -0.04
 
loading
KEY STATS
Previous Close:
$1.42
Market Cap:
$55.26M
24h Volume:
289.82K
1D Range:
$1.34 - $1.44
52W Range:
$1.21 - $4.01
Primary Exchange:
COMPANY PROFILE
NameNameMediWound Ltd. - Ordinary Share
sectorSectorHealthcare (1251)
industryIndustryBiotechnology (741)
webWebmediwound.com
phonePhone972 7 797 14100
employeeEmployee76
chart-line-icon Latest SEC Filings
twitter-icon MDWD's Discussions on Twitter
location42 Hayarkon Street, Yavne, Israel (8122745)
News New Options Data Financials Holders Transactions Discussions Predictions
Oct-07-22 06:00AM MediWound Announces Closing of the Concurrent Registered Direct and Private Placement OfferingsGlobeNewswire Inc.
Sep-23-22 03:42AM Why Avenue Therapeutics Shares Surged Around 106%; Here Are 87 Biggest Movers From YesterdayBenzinga
Sep-22-22 03:10AM Dow Turns Higher; Crude Oil Rises 0.7%Benzinga
12:26PM Why MediWound Is Trading Lower By Around 18%, Here Are 48 Stocks Moving In Thursday's Mid-Day SessionBenzinga
Sep-22-22 12:26PM Nasdaq Drops Over 100 Points; Spero Therapeutics Shares Spike HigherBenzinga
08:02AM MediWound Announces Concurrent Registered Direct and Private Placement Offerings Priced At-the-Market of Approximately $30 MillionGlobeNewswire Inc.
Aug-09-22 08:45AM MediWound (MDWD) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research
07:30AM MediWound Reports Second Quarter 2022 Financial Results and Provides Company UpdatesGlobeNewswire Inc.
Aug-08-22 05:35AM FibroGen (FGEN) Reports Q2 Loss, Misses Revenue EstimatesZacks Investment Research
04:05AM MediWound Enhances Its Board and Executive Leadership TeamGlobeNewswire Inc.
May-17-22 08:15AM MediWound (MDWD) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research
07:01AM MediWound Announces CEO TransitionGlobeNewswire Inc.
May-16-22 05:25AM Ayala Pharmaceuticals, Inc. (AYLA) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research
May-12-22 05:35AM 4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue EstimatesZacks Investment Research
08:42AM The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And MoreBenzinga
About MediWound Ltd. - Ordinary Share
MediWound Ltd., an integrated biopharmaceutical company, focuses on developing, manufacturing, and commercializing novel therapeutics products to address unmet needs. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns in the European Union, Israel, and Argentina. The company also develops EscharEx, which is in Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.
Real-Time Dow Stock List Congresswoman Nancy Pelosi Stock Tracker Top 100 popular stocks on Robinhood
Open in Yahoo | Open in Google | Open in Finviz
Cap:    |  Volume (24h):